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A human papillomavirus type 11 (HPV-11) early gene promoter, PE1ˆE4, in the E7 open reading frame and involved in
the transcription of E1ˆE4 and E1ˆE4, L1 mRNAs was characterized by chloramphenicol acetyl transferase (CAT) assay,
gel-shift assay, in vitro transcription, and primer extension. By CAT assay with CAT-expression plasmids containing various
portions of the HPV-11 genome from nucleotide position (nt) 235 to nt 743, we identified a 112-basepair (bp) sequence (nt
632–743) that had high promoter activity and a 188-bp upstream sequence from nt 395 to nt 572 that strongly suppressed
activity. The 112-bp sequence contained a 7-bp repeat (7-bp Rep) with high homology to the Sp1-binding motif (BM) in the
E6 promoter of HPV-11 but lacked an identifiable TATA-box. A cellular protein other than Sp1 bound to the 7-bp Rep.
Removal of a 21-bp segment (nt 632–652) containing the 7-bp Rep significantly reduced activity. By in vitro transcription
assay and primer extension, one of the transcription start sites was mapped to near nt 719. These results suggested that
a cellular protein that binds to the 7-bp Rep may act as an activator for PE1ˆE4. q 1996 Academic Press, Inc.
INTRODUCTION amplification of cDNAs, a bicistronic mRNA, E1ˆE4, L1,
which encodes E1ˆE4 and L1 proteins, was detected (Ro-
Human papillavirus virus type 11 (HPV-11) is a muco- tenberg et al., 1989; Tomita and Simizu, 1993). Thus, tran-
sal type HPV that induces benign tumors such as condy- scription of the mRNA encoding the E1ˆE4, E1, E1-M, E2,
loma acuminata and laryngeal papilloma. In these tumors E2-C, and L1 protein appears to be driven by the same
and in HPV-11-infected human tissue implanted into promoter. In the work described in this paper, we character-
athymic mice, E1ˆE4 mRNA, which encodes the E1ˆE4 ized the promoter PE1ˆE4 in the E7 ORF of HPV-11.
fusion protein, is the most abundant viral mRNA (Nasseri
et al., 1987; Chow et al., 1987; Stoler et al., 1990). By R- MATERIALS AND METHODS
loop analysis (Chow et al., 1987), the 5*-ends of the
CAT expression plasmidsE1ˆE4 mRNAs and of other mRNAs encoding E1-M, E2-
C, and E2 proteins have been mapped to near nucleotide To construct CAT expression assay plasmids, we used
(nt) 700 in the E7 open reading frame (ORF). Smotkin et pSV2CAT (Gorman et al., 1982), pTV119N (Takara Shuzo
al. (1989) used S1 nuclease to map the 5*-ends of the Co. Ltd., Japan), pCAT-Enhancer (Promega Co. Ltd., Mad-
E1ˆE4 mRNAs to a heterogeneous cluster of sites around ison, WI). Promoter activity of the BamHI (nt 7072) to
nt 674–714, and Nasseri et al. (1987) mapped the 5*- ApaLI (nt 743) sequence within the HPV 11 genome was
ends to nt 716 by cDNA cloning. Therefore, a promoter tested using constructs derived from pSV2CAT, pCAT-
has been presumed to exist in the E7 ORF (Chow et al., Enhancer, and pTV119N. pCAT/19 was constructed by
1987; Smotkin et al., 1989). blunt-end ligating into the EcoRI site of pTV119N a
The promoter of HPV-11 most studied is the E6 pro- pSV2CAT HindIII– BamHI fragment containing the bacte-
moter, which drives transcription of the E6-specific rial chloramphenicol acetyl transferase (CAT) gene and
mRNA. However, other promoters have yet to be studied the SV40 poly(A) signal, but lacking the SV40 enhancer.
in detail. A promoter in the E7 ORF would be expected Next, the BamHI (nt 7072) to ApaLI (nt 743) sequence
to be highly active during HPV replication in tumors in was inserted into the XbaI site of pCAT-Enhancer, after
that expression of E1ˆE4 mRNA occurs very early during addition of XbaI linker and obtained pBA/CAT-enhancer.
cellular differentiation and increases after the onset of Then, four CAT expression assay plasmids were con-
viral DNA replication. Eventually, E1ˆE4 mRNA accumu- structed replacing a part of pTV119 and CAT gene se-
lates to more than 98% of virus mRNAs in the epithelium quences (from the HindIII site in pTV119 to the EcoRI
(Chow et al., 1987). By polymerase chain reaction (PCR) site in pSV2CAT) with various-lengths of the E7 ORF-CAT
gene fusion sequence from NdeI (nt 235 in E7 ORF) to
the XbaI site (nt 2266 in pCAT-Enhancer) in pBA/CAT-1 To whom reprint requests should be addressed. Fax: /81(43)
2262045. E-mail: tomita@med.m.chiba-u.ac.jp. Enhancer. The resulting plasmids pNNDPA/CAT pNDPA/
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CAT, pDPA/CAT, and pPA/CAT, contained fragments of extract was prepared according to the methods de-
scribed by Gigman et al. (1983), with minor modifications.the HPV 11 E7 ORF beginning at NdeI (nt 235), NdeI (nt
351), DraI (nt 392), or PstI (nt 572), respectively, and end- The reaction mixture (20 ml) contained 1 ml of HeLa-cell
nuclear extract, 2 ml of 51 binding buffer (55 mM HEPES,ing at ApaLI (nt 743). pNNDPA/CAT was then used to
construct a fifth plasmid, pNNDPA/CAT, by restriction pH 7.9, 250 mM KCl, 40 mM MgCl2 , 55% glycerol, 0.5
mM EDTA, and 5 mM dithiothreitol (DTT)), 1 ml of poly(dI –enzyme digestion and removal of the PstI–ApaI se-
quence, blunting, and ligation. The sequences of the E7 dC), 1 ml (20 fmmol) of 32P-labeled probe and 2 to 5 ml
of competitor. The binding reaction was carried out onORF-CAT junction in the CAT expression assay plasmids
(from nt 739 of HPV11 to nt 2271 in pCAT-Enhancer) were ice for 10 min, and then the products were analyzed
by electrophoresis in 5% polyacrylamide in 0.51 Tris–GTGCACTCTAGA.
Several plasmids were constructed for determining the borate–EDTA buffer (45 mM Tris–borate, pH 8.0, 2 mM
EDTA).effects on promoter activity of the 5*-region of the HPV-
11 noncoding region (NCR). The NdeI–ApaLI (nt 235 –
743) sequence of pNNDPA/CAT was replaced with the In vitro transcription and primer extension
BamHI–AccII NCR sequence of HPV-11 (nt 7072 to nt
A 439-bp DNA fragment, consisting 177 bp of HPV-117513) to construct pBA/CAT. Then, pBA/NDPA/CAT and
DNA and 262 bp of the CAT gene, was used for in vitropBA/PA/CAT were obtained by inserting the BamHI–Ac-
transcription with a HeLa cell extract transcription sys-cII sequence into the NdeI (nt 351) and PstI (nt 572) sites
tem (Promega Co. Ltd.). The 25-ml reaction mixture con-of pNDPA/CAT and pPA/CAT, respectively.
tained 8 units of HeLa nuclear extract, 3 mM MgCl2 , 50Plasmids for mapping of a minimum promoter se-
to 100 ng of the DNA fragment, and 0.4 mM of eachquence were obtained by removing portions of the HPV-
dNTP. To radioactively label the RNA product, the con-11 E7 promoter sequence from pPA/CAT and pBA/PA/
centration of dGTP was decreased to 0.016 mM and 5CAT. Portions of the promoter and part of the CAT gene
mCi of [32P]GTP (3000 Ci/mmol) was included. The reac-in each of these plasmids were amplified by PCR using
tion was carried out at 307 for 60 min and then the 32P-various primer sets with a restriction site at the 5*-end.
labeled product was analyzed on a 6% polyacrylamideThen, the promoter and CAT gene sequence in pPA/CAT
sequencing gel. Restriction enzyme (HapII)-digested andand pBA/PA/CAT were replaced with these PCR products 32P-labeled pUC19 and pTV119N DNAs (Takara Shuzo,to yield p623A/CAT, p632A/CAT, p653A/CAT, pBA/632A/
Co. Ltd.) were used as size markers. The unlabeled tran-CAT, and pBA/653A/CAT.
scription product was prepared and used as a template
for primer extension. The 25-ml reaction mixture con-CAT assay
tained 30 mM Tris–HCl, pH 8.3, 15 mM MgCl2 , 8 mM
HeLa cells were grown in Eagle’s MEM with 10% fetal DTT, 4 mM of each dNTP, 10 ml of the template RNA, 1
calf serum. Fifteen micrograms of each plasmid was ml of 32P-labeled HS21 primer, which has a sequence
mixed with 61 106 cells in glucose buffer (20 mM HEPES, corresponding to nt 2341–2359 of plasmid pCAT-En-
N-2-hydroxyethylpiperazine-N*-2-ethanesulfonic acid, pH hancer, 0.22 mg of actinomycin D, and 5 units of reverse
7.2, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4 , 6 mM transcriptase. The reaction was carried out at 377 for 60
glucose). Cells were transfected with each plasmid in a min, stopped by addition of 12 ml of sequencing stop
GTE-10 electroporation apparatus (Shimadzu Co. Ltd., buffer, and heated at 907 for 3 min. The product was
Japan) and cultured in Eagle’s MEM with 10% fetal calf analyzed in a 6% sequencing gel in which the sequencing
serum. Two days later, CAT assays were carried out by products of an M13mp18-ssDNA/M13-47 primer reaction
methods described elsewhere (Shirasawa et al., 1994). as were included as a size marker.
Radioactivities of the acetylated products were calcu-
lated using the BAS-2000 Bio-imaging analyzer (Shira- RESULTS
sawa et al., 1994). Assays were done at least three times
Promoter activity of HPV-11 nt 235 to nt 743and mean values were calculated.
To determine the sequence of PE1ˆE4 required pro-Gel-shift assay
moter activity, various portions of HPV-11 DNA from the
NdeI site at nt 235 to the ApaLI site at nt 743 (Fig. 1A)Double-stranded (ds)-oligonucleotides (5*-GATGAG-
GTGGACAAGGTGGA) that match the Sp1 binding motif were cloned into the HindIII site of pCAT/19 (Fig. 1B),
and CAT assays were carried out using HeLa cells. As(BM)-like sequence in the E7 ORF (7-basepair (bp) re-
peat, 7-bp Rep) were labeled with [g-32P]dATP and used shown in Figs. 1C-1 and 1C-2, the highest promoter activ-
ity was observed in pPA/CAT, suggesting that the PstI –as probe. Unlabeled 7-bp Rep and a ds-oligonucleotide
(5*-ATTCGATCGGGGCGGGGCGAGC) (SVSp1), which ApaLI sequence in the E7 ORF contains one or more
sequences that are essential for promoter function. Thecontains Sp1-BM of the SV40 early promoter (Promega,
Co. Ltd.), were used as competitors. HeLa-cell nuclear relatively high background level observed in the pCAT/19
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FIG. 1. Promoter activity of HPV-11 sequence from BamHI (nt 7072) to ApaLI (nt 743). (A) HPV-11 genome DNA containing E6, E7, and a part of
E1 ORFs. The restriction sites are shown with nucleotide numbers. The locations of E6 and E7 promoters and a promoter in the E7 ORF, PE1ˆE4
are indicated by arrows and nucleotide numbers. (B) CAT-expression plasmids. (C, 1) Thin-layer chromatography of acetylated and nonacetylated
chloramphenicol. (C, 2) The degree of acetylation was determined as described under Materials and Methods and mean values are shown as
relative CAT activity to the activity of pPA/CAT, which is depicted as 100.
reaction, the negative control, suggested that nonspecific shown in Fig. 2B-2, addition of the BamHI–AccII se-
quence decreased nonspecific transcription of pCAT/19transcription initiation may occur in pCAT/19. CAT activi-
ties of the other plasmids, containing NNDP, NDP, and from 17 to 7.8 relative to the activity of the pPA/CAT(100).
This result indicated a partial elimination by the BamHI –DP sequences, were lower than that of pCAT/19. This
suggested that the NdeI –PstI (nt 235–572) sequence or AccII sequence of the nonspecific transcription initiation
from the plasmid sequence. However, in pBA/PA/CAT,even the DraI– PstI (nt 392–572) had a strong sup-
pressive effect on PE1ˆE4. high CAT activity was still observed, demonstrating again
the presence of a promoter in the PstI–ApaLI sequence.To eliminate nonspecific transcription initiation from
the plasmid sequence, the 5*-terminus of the noncoding
Determination of minimum promoter sequenceregion (NCR), BamHI– AccII (Fig. 2A), was inserted up-
stream of the CAT, NDP, and PA sequences of pCAT/19, The PstI–ApaLI sequence contains the E2-binding mo-
tif (E2-BM) at nt 585–596, 7-bp Rep sequences, AGG-pNDPA/CAT, and pPA/CAT, respectively (Fig. 2B-1). As
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FIG. 2. Effects of the 5*-end region of the HPV-11 NCR. (A) The structure of the HPV-11 genome from BamHI (nt 7072) to AccII (nt 7513). (B, 1)
CAT expression plasmids. (B, 2) Relative CAT activity of pBA/PA/CAT, which is depicted as 100.
TGGA, at nt 636–642 and at nt 645–651, and an initiator- the promoter activities, though these were not abolished
completely. These results suggested that nt 572–652,like sequence (INR-like sequence) TACCAA, at nt 683-
688 (Fig. 3A). To more precisely analyze the PE1ˆE4 se- which contains 7-bp Rep sequences, is required for the
transcriptional activity of PE1ˆE4.quence, we prepared deletion mutants (Fig. 3B-1) and
assayed for promoter activity. As shown in Fig. 3B-2,
deletion of nt 572–622 or nt 572–631 from pPA/CAT and Gel-shift assay
deletion of nt 572–631 from pBA/PA/CAT did not impair
promoter activities. In contrast, deletions of nt 572–652 Next, we used gel-shift assay to examine protein bind-
ing on the 7-bp Rep. As shown in Fig. 4, a protein fromfrom pPA/CAT and pBA/PA/CAT significantly decreased
FIG. 3. Mapping of a minimum promoter sequence. (A) Locations of motifs within nt 572-743. (B, 1) CAT-expression plasmids. (B, 2) Relative CAT
activity to the activity of pPA/CAT, which is depicted as 100.
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E1ˆE4 mRNA (Chow et al., 1987). Thus, it is presumed
that PE1ˆE4, which lacks an identifiable TATA ele-
ment, would be highly active in tumors caused by HPV-
11. However, early promoters of HPVs are relatively
weak in cultured cells when examined by transient
transfection assay. With CAT-expression plasmids, we
showed that the sequence from nt 632 to nt 743 (PstI –
ApaLI) has the highest promoter activity and that the
upstream sequence from nt 235 to nt 572 (NdeI – PstI)
strongly suppressed activity. The construct, pCAT/19,
showed relatively high nonspecific transcription initia-
tion from the vector’s sequence. The HPV-11 NCR se-
quence (BamHI – AccII, nt 7072 – 7513) has been sup-
posed to contain negative regulatory elements that
acts at the level of mRNA stability and a mRNA 3*-
processing poly(A) signal at nt 7457 – 7462. Because
the sequence is similar with the negative regulatory
elements of HPV-16 late mRNA (Kennedy et al., 1990,
1991). Therefore, nonspecific transcription in the plas-
mid sequence would terminate within the BamHI – Ac-
cII sequence. Furthermore, the BamHI – AccII se-
quence has shown to contain a constitutive enhancer
at nt 7224 – 7496, when it was assayed for SV40 pro-FIG. 4. Binding of HeLa nuclear extract to the 7-bp Rep. Competition
gel-shift assay was performed as described under Materials and Meth- moter (Auborn et al., 1989). However, we could not
ods. Double stranded (ds)-competitors, 7-bp Rep and SVSp1 (SV40 see its significant effect on the minimum promoter in
early promoter Sp1 binding motif), the fold excess at which each was the E7 ORF.
used is indicated. H.E., HeLa nuclear extract.
It has been proposed that transcription factors such
as the TFIID complex, which contains TATA-box bind-
HeLa nuclear extract bound to ds-oligonucleotide con- ing proteins (TBPs), interact similarly with ‘‘TATA-less’’
taining the 7-bp Rep sequence, 5*-GATGAGGTGGAC- and ‘‘TATA-containing’’ promoters (Conaway and Con-
AAGGTGGA. Addition of either 20- or 200-fold excess of away, 1993). At least two models have been proposed
unlabeled oligonucleotide inhibited binding. However, a to explain how TATA-less promoters work. (i) TATA-
400-fold excess of another oligonucleotide, 5*-ATTCGA- less promoters usually contain an initiator (INR) ele-
TCGGGGCGGGGCGAGC, which contained Sp1-BM of ment that specifically interacts with the transcription
the SV40 early promoter, did not inhibit binding. More- initiation complex (Kaufmann and Smale, 1994). (ii) A
over, purified Sp1 (Promega Co. Ltd.) did not bind to the transcription activator, Sp1, can activate most cellular
7-bp Rep (data not shown). These results showed that and viral TATA-less promoters, depending on the
the binding protein was not Sp1. presence of a coactivator (Pugh and Tjian, 1992). Ac-
cording to these models, it seems likely that, inIn vitro transcription and primer extension
PE1ˆ E4, nt 632 – 743 should be sufficient to supportTo determine the transcription initiation site, an in vitro
transcription and that the 7-bp Rep would interact withtranscription assay was done using the 439-bp DNA frag-
one or more cellular proteins that could function asment from pPA/CAT (Fig. 5A). As shown in Fig. 5B, when
activators. The 7-bp Rep has relatively high homology50 or 100 ng of template DNA was used, two labeled
to AAGAGGAGGA, the Sp1-BM, which is located im-products were detected. The upper and lower bands rep-
mediately upstream of the E2-BM in the E6 promoter ofresent RNAs of approximately 430 and 293 bases, re-
HPV-11 (Gloss and Bernard, 1990). However, a cellularspectively. However, the upper band may have been a
protein other than Sp1 bound to the 7-bp Rep. Thesenonspecific product in that the same band was observed
results imply that the cellular protein functions as aneven when the HeLa nuclear extract was pretreated at
activator for PE1ˆE4. A possible INR function for the427 for 15 min before use (data not shown). Primer exten-
7-bp Rep cannot be overlooked, however, since re-sion using an HS21 primer yielded a 120-bp single-strand
moval of the 7-bp Rep significantly reduced the activ-DNA (Fig. 5B). This suggested that one of the transcrip-
ity. Furthermore, promoter activity of p632A/CAT, buttion initiation sites on pPA/CAT was near nt 719.
not p653A/CAT increased three- to fourfold (data not
DISCUSSION shown) upon cotransfection of an adenovirus type 5
E1A-expression plasmid, implying that nt 632 – 743It has been shown that more than 98% of viral RNA
in HPV-11-infected condyloma acuminata consists of function as a minimum promoter. In vitro transcription
AID VY 8206 / 6a21$$$582 10-17-96 14:30:27 vira AP: Virology
272 TOMITA, SHIGA, AND SIMIZU
FIG. 5. Mapping of a transcription initiation site. (A) Map of the DNA fragment used for in vitro transcription assay. (B) Products of in vitro
transcription assay. Arrow indicates 289-bases-long RNA band. Markers: HpaII-digested pTV119N (M1) and pUC19 (M2), M1: 584, 489, 431, 404,
293, 242, 190 bp; M2: 501/489, 431, 404, 331, 242, 190 bp. Lane 1, 50 ng DNA; lane 2, 100 ng DNA. (C) Primer extension assay. Lanes 1–2: Dideoxy
sequencing patterns (A and C) of m13mp19 DNA with M13-47 primer. Lane 3: 120-bases-long single-strand DNA (arrow).
and primer extension showed that one of the transcrip- to ACCGN4CGGT (Hirochika et al., 1988), could be one of
the reasons for weak activation.tion initiation sites is near nt 719. The sequence TAC-
CAAA at nt 683 – 689, about 30 bp upstream of a pre- Recently, Grassmann et al. (1996) identified a differen-
tiation-inducible promoter in the E7 ORF of HPV-16 indicted transcription initiation site, may act as an INR
in vivo, because the sequence is similar to that of raft cultures of a cell line containing high copy numbers
of episomal HPV-16 DNA and that the transcript initiatedthe SV40 late promoter, TACCTAA, to which the TFIID
protein binds (Wiley et al., 1992). However, the possi- from the promoter had a coding potential for an E1ˆE4
fusion protein. They have discussed the differentiation-bility that the 7-bp Rep acts as an INR and as the
transcription start at near nt 674 should be considered, dependent activation of the promoter in relation to a pos-
sible binding of C/EBP protein on a GCAAT motif, a vari-because removal of the 7-bp Rep significantly reduced
promoter activity. ant of CCAAT, which locates just 29 bp upstream of the
transcription initiation site. In HPV-11, the mechanism byTo examine the suppressive effect of the NdeI–PstI se-
quence (nt 235–572) on the SV40 promoter, we inserted which the NdeI–PstI sequence of HPV11 suppresses the
PE1ˆE4 activity is unclear. However, it may be of interestit upstream of or downstream from the SV40 promoter.
When the sequence was inserted immediately upstream to study the putative binding of certain proteins, such
as Oct-1 and YY-1, that strongly suppress the HPV-18of the promoter in sense orientation, activity was sup-
pressed by 41.6% (data not shown), suggesting that the promoter (zur Hausen, 1994) or a possible inhibition of
the suppression by C/EBP protein binding on GCAAT/NdeI–PstI sequence may regulate PE1ˆE4 in tumors.
However, cotransfection of an HPV-11 E2 expression plas- CCAAT motifs which locate at nt 326–330, nt 379–383,
and nt 610–614 of HPV-11 DNA.mid, pRS-E2-11 (Hirochika et al., 1987), with pNDPA/CAT
showed that the E2 protein weakly activated the promoter Frattini et al. (1996) have reported differentiation-de-
pendent and episomal gene-dependent late gene ex-(1.58-fold), but did not overcome the suppressive effect of
the NdeI–PstI sequence (not shown in figure), suggesting pression of HPV-31 with raft cultures, in which amplifica-
tion of viral DNA and production of viral particles oc-that the E2 binding motif ACCN6GGT at nt 585–596 does
not have a regulatory function in vivo. The low binding curred. In natural tumor, such as condyloma acuminata,
the HPV-11 DNA rapidly replicates as episome and isaffinity of E2 to the ACCN6GGT, compared with the binding
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the E2 transactivator and the TATA box binding protein depends onnot integrated into the host cell chromosome. This might
core promoter structure. EMBO J. 13, 147–157.be one of the reasons why E1ˆE4 mRNA is expressed
Hirochika, H., Broker, T. R., and Chow, L. T. (1987). Enhancers and
so abundantly in natural tumors. trans-acting E2 transcriptional factors of papillomaviruses. J. Virol.
61, 2599–2606.
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